Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.43 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739916 | 1.00 | GLP1R (0.49) | GLP1RMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL25771606 | 0.84 | TSHR (0.47) | GLP1RMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL23618033 | 0.84 | NR1H2 (0.47) | GLP1RMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL1343778 | 0.81 | NPSR1 (0.45) | NPSR1ALDH1A1GAAL3MBTL1LMNA | |
| SCHEMBL29922648 | 0.81 | NPSR1 (0.45) | NPSR1ALDH1A1GAAL3MBTL1LMNA | |
| SCHEMBL5886537 | 0.81 | MAPT (0.43) | GLP1RMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL5886482 | 0.79 | KDM4E (0.42) | GLP1RMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL21120427 | 0.78 | GLP1R (0.49) | GLP1RMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL31208503 | 0.78 | MAPT (0.40) | GLP1RMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL4041010 | 0.78 | ALDH1A1 (0.45) | GLP1RMAPTNPSR1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595245-B2 | Inhibitors of MET kinase | CELYN THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2026-01-01 | — | — | US | disclosed |
| US-12492184-B2 | Heteroaryl compounds, preparation methods and uses thereof | InventisBio Co., Ltd. (CN) | 2025-12-09 | — | — | US | disclosed |
| EP-4551559-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | Accro Bioscience (HK) Limited (HK) | 2025-05-14 | — | — | EP | disclosed |
| CN-119954775-A | Heteroaryl compounds, methods of making and uses thereof | 益方生物科技(上海)股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119954772-A | Heteroaryl compounds, methods of making and uses thereof | 益方生物科技(上海)股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448510-A1 | INHIBITORS OF MET KINASE | Kinnate Biopharma Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20060135367-A1 | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds | NEUROGEN CORPORATION (US) | 2006-06-22 | — | — | US | disclosed |
| EP-1594848-A1 | ARYL ACID PYRIMIDINYL METHYL AMIDES, PYRIDAZINYL METHYL AMIDES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
| WO-2005085248-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1549636-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | Neurogen Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005051906-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004074259-A1 | ARYL ACID PYRIMIDINYL METHYL AMIDES, PYRIDAZINYL METHYL AMIDES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION | 2004-04-22 | — | — | US | disclosed |
| WO-2004031174-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135367-A1 | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds | GABRA2, GABRA1, GABRA5 | GLP1R 531/4885MAPT 1094/4885NPSR1 110/4885 |
| US-12595245-B2 | Inhibitors of MET kinase | MET, ABL1, ERBB2 | GLP1R 1464/4885MAPT 2891/4885NPSR1 3014/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | GLP1R 1870/4885MAPT 908/4885NPSR1 4216/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | GLP1R 1870/4885MAPT 908/4885NPSR1 4216/4885 |
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | JAK1, JAK2, TYK2 | GLP1R 744/4885MAPT 4800/4885NPSR1 683/4885 |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | GLP1R 1712/4885MAPT 4825/4885NPSR1 3090/4885 |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | MAP3K1, MAP3K21, MAP3K2 | GLP1R 2684/4885MAPT 3249/4885NPSR1 2112/4885 |
| US-12492184-B2 | Heteroaryl compounds, preparation methods and uses thereof | TYK2, IL2, IL23R | GLP1R 1365/4885MAPT 1826/4885NPSR1 3303/4885 |
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | GABRA5, GABRA1, GABRA2 | GLP1R 537/4885MAPT 986/4885NPSR1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.